Today, the Title of Reporting Person: Chief Medical and Scien of Puma Biotechnology (PBYI), Richard Paul Bryce, sold shares of PBYI for $2,471.
Following Richard Paul Bryce’s last PBYI Sell transaction on January 04, 2019, the stock climbed by 6.0%. In addition to Richard Paul Bryce, 2 other PBYI executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Puma Biotechnology’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $62.63 million and GAAP net loss of $14.2 million. In comparison, last year the company earned revenue of $21.6 million and had a GAAP net loss of $64.1 million. The Company has a Price to Book ratio of 22.7524. Currently, Puma Biotechnology has an average volume of 572.3K.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $40.20, reflecting a 44.8% upside.
The insider sentiment on Puma Biotechnology has been negative according to 22 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.
